- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- November 2024
- 140 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 196 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- February 2025
- 118 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- February 2025
- 134 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- February 2025
- 149 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- September 2024
- 138 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- May 2024
- 128 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 140 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 128 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- April 2024
- 181 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- July 2024
- 172 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Drug Pipelines
- June 2024
- 180 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 260 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- June 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more